GRAMD1C

Across TCGA pan-cancer cohorts, GRAMD1C mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GRAMD1C data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GRAMD1C mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GRAMD1C expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where GRAMD1C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.662	.009	7	view →
GBM	OS	Median	All	0.594	0.454	.025	4	view →
LUAD	DFS	Median	II,III,IV	0.215	0.671	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GRAMD1C–CCRCC (OS)

Open the CCRCC breakdown →